MedTrace Logo

Clemizole HCl for Subjects With Hepatocellular Carcinoma

NCT03069508 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-03-03

No results posted yet for this study

Summary

This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.

Conditions

Interventions

DRUG

Clemizole Hydrochloride

Clemizole Hydrochloride will be administered orally for up to 24 weeks

Sponsors & Collaborators

  • Eiger Group International, Inc.

    lead INDUSTRY

Principal Investigators

  • Cihan Yurdaydin, MD · University of Ankara

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2017-12-31
Completion
2018-01-31
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03069508 on ClinicalTrials.gov